VEGFR2_D1-7, Human, Recombinant, S. frugiperda

Recombinant, human VEGFR-2 consisting of all 7 immunoglobulin-like extracellular domains, but lacking the single transmembrane region and the intracellular split tyrosine kinase domain expressed in S. frugiperda insect cells. Contains all of the domains necessary for high affinity binding to VEGF. VEGFR-2 has a lower affinity for VEGF165 than VEGFR-1. However, VEGFR-2 has a higher signaling activity and is reported to mediate almost all observed endothelial cell responses to VEGF, including the increased microvascular permeability and endothelial cell proliferation. VEGFR-2 requires heparin for binding VEGF165.

Measured by the ability to inhibit VEGF165-induced proliferation in human umbilical vein endothelial (HUVE) cells

Lyophilized from 100 mM NaCl, 25 mM MES, pH 5.5.

Following reconstitution, aliquot and freeze (-70°C). Stock solutions are stable for up to 6 months at -70°C. Avoid freeze/thaw cycles of solutions.

Robinson, C.J., and Stringer, S.E. 2001 J. Cell Sci.114, 853.
Roeckl, W., et al. 1998. Exp. Cell Res.241, 161.

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Toxicity: Standard Handling (A)